PART I . Overview We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimers disease, or AD. Alzheimers disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. Alzheimers disease is currently estimated to affect approximately seven million people in the United States and approximately 55 million peo...
Q2 FY2026 — expected 2026-08-12
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | ABOS | discussed_in_filing Cybersecurity | |
| topic_mention | ABOS | discussed_in_filing Trusted Computing | |
| topic_mention | ABOS | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ABOS | discussed_in_filing Capital Expenditure | |
| topic_mention | ABOS | discussed_in_filing Regulation | |
| topic_mention | ABOS | discussed_in_filing Healthcare & Bio | |
| topic_mention | ABOS | discussed_in_filing Cybersecurity | |
| topic_mention | ABOS | discussed_in_filing Trusted Computing | |
| topic_mention | ABOS | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ABOS | discussed_in_filing Capital Expenditure | |
| topic_mention | ABOS | discussed_in_filing Regulation | |
| topic_mention | ABOS | discussed_in_filing Healthcare & Bio | |
| topic_mention | ABOS | discussed_in_filing Cybersecurity | |
| topic_mention | ABOS | discussed_in_filing Trusted Computing | |
| topic_mention | ABOS | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ABOS | discussed_in_filing Capital Expenditure | |
| topic_mention | ABOS | discussed_in_filing Regulation | |
| topic_mention | ABOS | discussed_in_filing Healthcare & Bio | |
| topic_mention | ABOS | discussed_in_filing Cybersecurity | |
| topic_mention | ABOS | discussed_in_filing Trusted Computing |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001628280-26-021413 | EDGAR | 84K words |
| 2025-03-27 | 2024-12-31 | 0001576885-25-000049 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001576885-24-000047 | EDGAR | — |
| 2023-03-27 | 2022-12-31 | 0001576885-23-000017 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001193125-22-086775 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001576885-25-000104 | EDGAR | 19K words |
| 2025-08-12 | 2025-06-30 | 0001576885-25-000093 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001576885-25-000065 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001576885-24-000098 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001576885-24-000092 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001576885-24-000064 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001576885-23-000062 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001576885-23-000050 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001576885-23-000025 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001193125-22-284583 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001193125-22-221297 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001193125-22-151851 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001628280-26-021189 | EDGAR | 3K words |
| 2026-03-16 | 0001628280-26-017885 | EDGAR | — |
| 2026-01-12 | 0001628280-26-001774 | EDGAR | — |
| 2025-11-12 | 0001576885-25-000102 | EDGAR | — |
| 2025-11-10 | 0001628280-25-050800 | EDGAR | — |
| 2025-08-12 | 0001576885-25-000091 | EDGAR | — |
| 2025-07-15 | 0001576885-25-000087 | EDGAR | — |
| 2025-06-05 | 0001576885-25-000072 | EDGAR | — |
| 2025-05-13 | 0001576885-25-000062 | EDGAR | — |
| 2025-03-27 | 0001576885-25-000044 | EDGAR | — |
81 total filings indexed. 54 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001576885 |
| Ticker | ABOS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report